OBJECTIVES: To determine factors associated with diabetes, insulin resistance, and abnormal glucose tolerance in older men with or at risk of HIV infection. METHODS: Diabetes was assessed by self-report in 643 men >or=49 years old with or at risk of HIV infection. In a subset of 216 men without previously diagnosed diabetes [including 90 HIV-uninfected men, 28 HIV-infected, antiretroviral-naive men, 28 HIV-infected men taking non-protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART), and 70 HIV-infected men taking PI-containing HAART], an oral glucose tolerance test with insulin levels was performed. HIV serology, CD4 cell count, weight, height and waist circumference were measured. Antiretroviral use, drug use, family history of diabetes, physical activity and sociodemographic data were obtained using standardized interviews. RESULTS: Of 643 participants, 116 (18%) had previously diagnosed diabetes. With the oral glucose tolerance test, 15 of 216 men (7%) were found to have undiagnosed diabetes and 40 (18%) impaired glucose tolerance. Factors independently associated with previously diagnosed diabetes included use of non-PI-containing HAART, methadone treatment, positive CAGE test for alcoholism, obesity and family history of diabetes. Factors independently associated with greater insulin resistance included waist circumference and heroin use. Factors independently associated with abnormal glucose tolerance (impaired glucose tolerance or diabetes) included age >or=55 years and Hispanic ethnicity. CONCLUSIONS: HIV-infected men with diabetes risk factors should undergo screening for diabetes regardless of HAART use. Interventions targeting modifiable risk factors, including overweight and physical inactivity, are warranted. The potential impact of opiate and alcohol abuse on glucose metabolism should be recognized in clinical care, and addressed in future research studies of HIV-infected persons.
OBJECTIVES: To determine factors associated with diabetes, insulin resistance, and abnormal glucose tolerance in older men with or at risk of HIV infection. METHODS:Diabetes was assessed by self-report in 643 men >or=49 years old with or at risk of HIV infection. In a subset of 216 men without previously diagnosed diabetes [including 90 HIV-uninfectedmen, 28 HIV-infected, antiretroviral-naive men, 28 HIV-infectedmen taking non-protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART), and 70 HIV-infectedmen taking PI-containing HAART], an oral glucose tolerance test with insulin levels was performed. HIV serology, CD4 cell count, weight, height and waist circumference were measured. Antiretroviral use, drug use, family history of diabetes, physical activity and sociodemographic data were obtained using standardized interviews. RESULTS: Of 643 participants, 116 (18%) had previously diagnosed diabetes. With the oral glucose tolerance test, 15 of 216 men (7%) were found to have undiagnosed diabetes and 40 (18%) impaired glucose tolerance. Factors independently associated with previously diagnosed diabetes included use of non-PI-containing HAART, methadone treatment, positive CAGE test for alcoholism, obesity and family history of diabetes. Factors independently associated with greater insulin resistance included waist circumference and heroin use. Factors independently associated with abnormal glucose tolerance (impaired glucose tolerance or diabetes) included age >or=55 years and Hispanic ethnicity. CONCLUSIONS:HIV-infectedmen with diabetes risk factors should undergo screening for diabetes regardless of HAART use. Interventions targeting modifiable risk factors, including overweight and physical inactivity, are warranted. The potential impact of opiate and alcohol abuse on glucose metabolism should be recognized in clinical care, and addressed in future research studies of HIV-infectedpersons.
Authors: Carlos Jericó; Hernando Knobel; Milagro Montero; Jordi Ordoñez-Llanos; Ana Guelar; Juan L Gimeno; Pere Saballs; Jose L López-Colomés; Juan Pedro-Botet Journal: Diabetes Care Date: 2005-01 Impact factor: 19.112
Authors: Michael P Dubé; Dajun Qian; Hannah Edmondson-Melançon; Fred R Sattler; Diane Goodwin; Carmen Martinez; Vanessa Williams; Debra Johnson; Thomas A Buchanan Journal: Clin Infect Dis Date: 2002-07-23 Impact factor: 9.079
Authors: Shruti H Mehta; Richard D Moore; David L Thomas; Richard E Chaisson; Mark S Sulkowski Journal: J Acquir Immune Defic Syndr Date: 2003-08-15 Impact factor: 3.731
Authors: Allison Longenberger; Jeong Youn Lim; Todd T Brown; Alison Abraham; Frank J Palella; Rita B Effros; Trevor Orchard; Maria Mori Brooks; Lawrence A Kingsley Journal: Future Virol Date: 2011-04 Impact factor: 1.831
Authors: Allison Longenberger; Jeong Youn Lim; Trevor Orchard; Maria Mori Brooks; Jennifer Brach; Kristen Mertz; Lawrence A Kingsley Journal: Futur HIV Ther Date: 2008-11
Authors: Anne K Monroe; Adrian S Dobs; Xiaoqiang Xu; Frank J Palella; Lawrence A Kingsley; Mallory D Witt; Todd T Brown Journal: J Acquir Immune Defic Syndr Date: 2011-10-01 Impact factor: 3.731
Authors: Andrea A Howard; Donald R Hoover; Kathryn Anastos; Xi Wu; Qiuhu Shi; Howard D Strickler; Stephen R Cole; Mardge H Cohen; Andrea Kovacs; Michael Augenbraun; Patricia S Latham; Phyllis C Tien Journal: J Acquir Immune Defic Syndr Date: 2010-06 Impact factor: 3.731
Authors: Andrea A Howard; Yungtai Lo; Michelle Floris-Moore; Robert S Klein; Norman Fleischer; Ellie E Schoenbaum Journal: AIDS Date: 2007-03-12 Impact factor: 4.177